@article{TCR16097,
author = {Kang Liu and Lin Yang and Xiao-Ming Zhang and Yi Zhou and Tao Zhu and Nan-Dong Miao and Yong-Jun Ren and Hao Xu and Xu-Li Min and Juan Peng and Ke Yang and Shi Yang},
title = {HIF-1α and VEGF levels for monitoring hepatocellular carcinoma treatment response to transcatheter arterial chemoembolization},
journal = {Translational Cancer Research},
volume = {6},
number = {6},
year = {2017},
keywords = {},
abstract = {Background: The purpose of the present study was to investigate the use of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) levels to monitor the treatment response to transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).
Methods: A total of 41 consecutive HCC patients underwent TACE were enrolled into this study. The serum levels of HIF-1α and VEGF were measured using enzyme-linked immunosorbent assays (ELISAs) 1 day before, and 1, 7 and 28 days after TACE therapy. The overall tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors criteria. Patients with a complete response or partial response comprised the responding group, whereas those with stable disease or progressive disease comprised the non-responding group. The differences in serum HIF-1α and VEGF levels before and after TACE therapy were subjected to analysis of nonparametric test, while correlations between serum HIF-1α and VEGF levels were examined using Pearson’s correlation analysis. Receiver-operating characteristic (ROC) curve was applied to analyze the evaluation value of factors for the response of TACE on the treatment of HCC. P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/16097}
}